Contrasting QIAGEN (NASDAQ:QGEN) and Graphite Bio (NASDAQ:GRPH)

Graphite Bio (NASDAQ:GRPHGet Rating) and QIAGEN (NASDAQ:QGENGet Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.


This table compares Graphite Bio and QIAGEN’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Graphite Bio N/A N/A N/A
QIAGEN 22.76% 20.58% 10.30%

Analyst Ratings

This is a breakdown of current ratings and target prices for Graphite Bio and QIAGEN, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Graphite Bio 0 2 4 0 2.67
QIAGEN 0 0 0 0 N/A

Graphite Bio presently has a consensus price target of $18.00, suggesting a potential upside of 319.58%. Given Graphite Bio’s higher possible upside, equities analysts plainly believe Graphite Bio is more favorable than QIAGEN.

Earnings and Valuation

This table compares Graphite Bio and QIAGEN’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Graphite Bio N/A N/A -$70.76 million N/A N/A
QIAGEN $2.25 billion 4.73 $512.60 million $2.21 21.23

QIAGEN has higher revenue and earnings than Graphite Bio.

Institutional and Insider Ownership

61.3% of Graphite Bio shares are owned by institutional investors. Comparatively, 66.4% of QIAGEN shares are owned by institutional investors. 0.3% of Graphite Bio shares are owned by insiders. Comparatively, 9.0% of QIAGEN shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


QIAGEN beats Graphite Bio on 7 of the 9 factors compared between the two stocks.

About Graphite Bio (Get Rating)

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

About QIAGEN (Get Rating)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Receive News & Ratings for Graphite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graphite Bio and related companies with's FREE daily email newsletter.